Opsonic antibodies to the surface M protein of group a streptococci in pooled normal immunoglobulins (IVIG)

Potential impact on the clinical efficacy of IVIG therapy for severe invasive group a streptococcal infections

Hesham E Basma, Anna Norrby-Teglund, Allison McGeer, Donald E. Low, Omar El-Ahmedy, James B. Dale, Benjamin Schwartz, Malak Kotb

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The surface M protein of group A streptococci (GAS) is one of the major virulence factors for this pathogen. Antibodies to the M protein can facilitate opsonophagocytosis by phagocytic cells present in human blood. We investigated whether pooled normal immunoglobulin G (IVIG) contains antibodies that can opsonize and enhance the phagocytosis of type M1 strains of GAS and whether the levels of these antibodies vary for different IVIG preparations. We focused on the presence of anti-M1 antibodies because the M1T1 serotype accounts for the majority of recent invasive GAS clinical isolates in our surveillance studies. The level of anti-M1 antibodies in three commercial MG preparations was determined by enzyme-linked immunosorbent assay (ELISA), and the opsonic activity of these antibodies was determined by neutrophil-mediated opsonophagocytosis of a representative MIT1 isolate. High levels of opsonic anti-M1 antibodies were found in all MG preparations tested, and there was a good correlation between ELISA titers and opsonophagocytic activity. However, there was no significant difference in the levels of opsonic anti-M1 antibodies among the various MG preparations or lots tested. Adsorption of IVIG with M1T1 bacteria removed the anti-M1 opsonic activity, while the level of anti-M3 opsonophagocytosis was unchanged. Plasma was obtained from seven patients with streptococcal toxic shock syndrome who received IVIG therapy, and the level of anti-M1 antibodies was assessed before and after IVIG administration. A significant increase in the level of type M1-specific antibodies was found in the plasma of all patients who received IVIG therapy (P < 0.006). The results reveal another potential mechanism by which IVIG can ameliorate severe invasive group A streptococcal infections.

Original languageEnglish (US)
Pages (from-to)2279-2283
Number of pages5
JournalInfection and Immunity
Volume66
Issue number5
StatePublished - May 1 1998

Fingerprint

Streptococcal Infections
Intravenous Immunoglobulins
Streptococcus
Immunoglobulins
Membrane Proteins
Anti-Idiotypic Antibodies
Antibodies
Therapeutics
Enzyme-Linked Immunosorbent Assay
Virulence Factors
Phagocytes
Septic Shock
Phagocytosis
Adsorption
Neutrophils
Immunoglobulin G
Bacteria

ASJC Scopus subject areas

  • Parasitology
  • Microbiology
  • Immunology
  • Infectious Diseases

Cite this

Opsonic antibodies to the surface M protein of group a streptococci in pooled normal immunoglobulins (IVIG) : Potential impact on the clinical efficacy of IVIG therapy for severe invasive group a streptococcal infections. / Basma, Hesham E; Norrby-Teglund, Anna; McGeer, Allison; Low, Donald E.; El-Ahmedy, Omar; Dale, James B.; Schwartz, Benjamin; Kotb, Malak.

In: Infection and Immunity, Vol. 66, No. 5, 01.05.1998, p. 2279-2283.

Research output: Contribution to journalArticle

Basma, Hesham E ; Norrby-Teglund, Anna ; McGeer, Allison ; Low, Donald E. ; El-Ahmedy, Omar ; Dale, James B. ; Schwartz, Benjamin ; Kotb, Malak. / Opsonic antibodies to the surface M protein of group a streptococci in pooled normal immunoglobulins (IVIG) : Potential impact on the clinical efficacy of IVIG therapy for severe invasive group a streptococcal infections. In: Infection and Immunity. 1998 ; Vol. 66, No. 5. pp. 2279-2283.
@article{e37ce348b4444f578a0bbec184c9293d,
title = "Opsonic antibodies to the surface M protein of group a streptococci in pooled normal immunoglobulins (IVIG): Potential impact on the clinical efficacy of IVIG therapy for severe invasive group a streptococcal infections",
abstract = "The surface M protein of group A streptococci (GAS) is one of the major virulence factors for this pathogen. Antibodies to the M protein can facilitate opsonophagocytosis by phagocytic cells present in human blood. We investigated whether pooled normal immunoglobulin G (IVIG) contains antibodies that can opsonize and enhance the phagocytosis of type M1 strains of GAS and whether the levels of these antibodies vary for different IVIG preparations. We focused on the presence of anti-M1 antibodies because the M1T1 serotype accounts for the majority of recent invasive GAS clinical isolates in our surveillance studies. The level of anti-M1 antibodies in three commercial MG preparations was determined by enzyme-linked immunosorbent assay (ELISA), and the opsonic activity of these antibodies was determined by neutrophil-mediated opsonophagocytosis of a representative MIT1 isolate. High levels of opsonic anti-M1 antibodies were found in all MG preparations tested, and there was a good correlation between ELISA titers and opsonophagocytic activity. However, there was no significant difference in the levels of opsonic anti-M1 antibodies among the various MG preparations or lots tested. Adsorption of IVIG with M1T1 bacteria removed the anti-M1 opsonic activity, while the level of anti-M3 opsonophagocytosis was unchanged. Plasma was obtained from seven patients with streptococcal toxic shock syndrome who received IVIG therapy, and the level of anti-M1 antibodies was assessed before and after IVIG administration. A significant increase in the level of type M1-specific antibodies was found in the plasma of all patients who received IVIG therapy (P < 0.006). The results reveal another potential mechanism by which IVIG can ameliorate severe invasive group A streptococcal infections.",
author = "Basma, {Hesham E} and Anna Norrby-Teglund and Allison McGeer and Low, {Donald E.} and Omar El-Ahmedy and Dale, {James B.} and Benjamin Schwartz and Malak Kotb",
year = "1998",
month = "5",
day = "1",
language = "English (US)",
volume = "66",
pages = "2279--2283",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Opsonic antibodies to the surface M protein of group a streptococci in pooled normal immunoglobulins (IVIG)

T2 - Potential impact on the clinical efficacy of IVIG therapy for severe invasive group a streptococcal infections

AU - Basma, Hesham E

AU - Norrby-Teglund, Anna

AU - McGeer, Allison

AU - Low, Donald E.

AU - El-Ahmedy, Omar

AU - Dale, James B.

AU - Schwartz, Benjamin

AU - Kotb, Malak

PY - 1998/5/1

Y1 - 1998/5/1

N2 - The surface M protein of group A streptococci (GAS) is one of the major virulence factors for this pathogen. Antibodies to the M protein can facilitate opsonophagocytosis by phagocytic cells present in human blood. We investigated whether pooled normal immunoglobulin G (IVIG) contains antibodies that can opsonize and enhance the phagocytosis of type M1 strains of GAS and whether the levels of these antibodies vary for different IVIG preparations. We focused on the presence of anti-M1 antibodies because the M1T1 serotype accounts for the majority of recent invasive GAS clinical isolates in our surveillance studies. The level of anti-M1 antibodies in three commercial MG preparations was determined by enzyme-linked immunosorbent assay (ELISA), and the opsonic activity of these antibodies was determined by neutrophil-mediated opsonophagocytosis of a representative MIT1 isolate. High levels of opsonic anti-M1 antibodies were found in all MG preparations tested, and there was a good correlation between ELISA titers and opsonophagocytic activity. However, there was no significant difference in the levels of opsonic anti-M1 antibodies among the various MG preparations or lots tested. Adsorption of IVIG with M1T1 bacteria removed the anti-M1 opsonic activity, while the level of anti-M3 opsonophagocytosis was unchanged. Plasma was obtained from seven patients with streptococcal toxic shock syndrome who received IVIG therapy, and the level of anti-M1 antibodies was assessed before and after IVIG administration. A significant increase in the level of type M1-specific antibodies was found in the plasma of all patients who received IVIG therapy (P < 0.006). The results reveal another potential mechanism by which IVIG can ameliorate severe invasive group A streptococcal infections.

AB - The surface M protein of group A streptococci (GAS) is one of the major virulence factors for this pathogen. Antibodies to the M protein can facilitate opsonophagocytosis by phagocytic cells present in human blood. We investigated whether pooled normal immunoglobulin G (IVIG) contains antibodies that can opsonize and enhance the phagocytosis of type M1 strains of GAS and whether the levels of these antibodies vary for different IVIG preparations. We focused on the presence of anti-M1 antibodies because the M1T1 serotype accounts for the majority of recent invasive GAS clinical isolates in our surveillance studies. The level of anti-M1 antibodies in three commercial MG preparations was determined by enzyme-linked immunosorbent assay (ELISA), and the opsonic activity of these antibodies was determined by neutrophil-mediated opsonophagocytosis of a representative MIT1 isolate. High levels of opsonic anti-M1 antibodies were found in all MG preparations tested, and there was a good correlation between ELISA titers and opsonophagocytic activity. However, there was no significant difference in the levels of opsonic anti-M1 antibodies among the various MG preparations or lots tested. Adsorption of IVIG with M1T1 bacteria removed the anti-M1 opsonic activity, while the level of anti-M3 opsonophagocytosis was unchanged. Plasma was obtained from seven patients with streptococcal toxic shock syndrome who received IVIG therapy, and the level of anti-M1 antibodies was assessed before and after IVIG administration. A significant increase in the level of type M1-specific antibodies was found in the plasma of all patients who received IVIG therapy (P < 0.006). The results reveal another potential mechanism by which IVIG can ameliorate severe invasive group A streptococcal infections.

UR - http://www.scopus.com/inward/record.url?scp=0031924674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031924674&partnerID=8YFLogxK

M3 - Article

VL - 66

SP - 2279

EP - 2283

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 5

ER -